Advanced search

Combine gene, variant, phenotype, region and year filters

Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.

Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
About your search

DPP4 and SARS are reported together in 2 articles.

Gene

DPP4

HGNC
HGNC:3009
26articles
26mentions
4variants with confirmed gene link
Most co-reported phenotypes (articles)
Reported variants (articles · ClinVar status)
Phenotype

SARS

347articles
347mentions
12co-reported genes shown
Most co-reported genes (articles)

Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.

Publications

2 records shown · first 60
TypeEntitySource evidenceConfidenceExtractor
geneDPP4“It has been suggested that the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pathway of entrance into the host cell might be assisted by dipeptidyl peptidase-4 (DPP4), leading to inflammation and cytokine storm, with replication into the airways and unfavorable effects in the lungs.”0.98hgnc_dict_v1
phenotypeSARS“It has been suggested that the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pathway of entrance into the host cell might be assisted by dipeptidyl peptidase-4 (DPP4), leading to inflammation and cytokine storm, with replication into the airways and unfavorable effects in the lungs.”0.93phenotype_alias_lexicon_v2
phenotypediabetes mellitus“Clinical Outcomes with the Use of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Among Patients with Diabetes Mellitus and COVID-19: A Systematic Review of Observational Studies.”0.98phenotype_alias_lexicon_v2
phenotypeCOVID-19“Clinical Outcomes with the Use of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Among Patients with Diabetes Mellitus and COVID-19: A Systematic Review of Observational Studies.”0.98phenotype_alias_lexicon_v2

A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.

PMID 28855003 | PMCID PMC7079582 | DOI 10.1099/jmm.0.000565 · Journal of medical microbiology · 2017 · 4 validated mentions
TypeEntitySource evidenceConfidenceExtractor
geneDPP4“The Medline database was searched using combinations and variations of terms, including 'Middle East respiratory syndrome coronavirus', 'MERS-CoV', 'SARS', 'therapy', 'molecular', 'vaccine', 'prophylactic', 'S protein', 'DPP4', 'heptad repeat', 'protease', 'inhibitor', 'anti-viral', 'broad-spectrum', 'interferon', 'convalescent plasma', 'lopinavir ritonavir', 'antibodies', 'antiviral peptides' and 'live attenuated viruses'.”0.98hgnc_dict_v1
phenotypeSARS“The current therapies have mainly been adapted from severe acute respiratory syndrome (SARS-CoV) treatments, including broad-spectrum antibiotics, corticosteroids, interferons, ribavirin, lopinavir-ritonavir or mycophenolate mofetil, and have not been subject to well-organized clinical trials.”0.93phenotype_alias_lexicon_v2
geneTMPRSS2“These include viral S protein targeting; inhibitors of host proteases, including TMPRSS2, cathepsin L and furin protease, and of viral M(pro) and the PL(pro) proteases; convalescent plasma; and vaccine candidates.”0.98hgnc_dict_v1
phenotypeMERS“A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.”0.93phenotype_alias_lexicon_v2